Skip to content
Screener

Trevi Therapeutics, Inc. TRVI Q1 2026 earnings

Reported May 5, 2026 · After market close

EPS-$0.09Miss by $0.02
EPS estimate-$0.07

Next report

Nov 12, 2026 (in 2 months)
EPS estimate-$0.13

Financials

Q1 2026

Income statement

See full
Operating income-$14.9M-30.0%
Net income-$13.2M-27.6%
EPS (diluted)-$0.090.0%

Balance sheet

See full
Cash & equivalents$19.4M+0.2%
Total debt$682.0K-28.7%
Total equity$172.1M+73.1%
Total assets$179.6M+67.8%

Cash flow

See full
Operating cash flow-$16.7M-23.8%
CapEx$102.0K—
Free cash flow-$16.8M—

Valuation & ratios

Valuation

as of 03/31/26
See full
Market cap$1.53B+152%
Enterprise value$1.51B+157%

Returns & leverage

See full
Return on equity-33.6%-9.4pp
Debt / equity0×0.0×
Current ratio24.8×+9.4×

FAQ

When did Trevi Therapeutics, Inc. report Q1 2026 earnings?
Trevi Therapeutics, Inc. (TRVI) reported Q1 2026 earnings on May 5, 2026 after market close.
What were Trevi Therapeutics, Inc.'s Q1 2026 revenue and EPS?
Trevi Therapeutics, Inc. reported eps of $-0.09 for Q1 2026.
Did Trevi Therapeutics, Inc. beat estimates in Q1 2026?
EPS missed the consensus estimate of $-0.07 by $0.02.
How did Trevi Therapeutics, Inc.'s Q1 2026 results compare year-over-year?
Compared to the same quarter a year prior, eps grew 0.0% from $-0.09.
Where can I find Trevi Therapeutics, Inc.'s Q1 2026 SEC filings?
You can read the 8-K earnings release (0001193125-26-206382) and the 10-Q periodic report (0001193125-26-206390) directly on SEC EDGAR. The filing index links above go to sec.gov.